Akers生物科學 AKER 深 滬
已收盤 04-16 16:00:00 美东时间
2.47
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 2.47
- 總市值 4113.24万
- 52周最高 41820.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 9900.00
- 委 比 0.00%
- 總股本 1665.28万
- 歷史最高 6566400.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 5760.00
- 每 手 1
- 風險率 0.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
Akero Therapeutics will be acquired by Novo Nordisk for up to $5.2 billion in cash. Akero shareholders will receive $54.00 per share in cash and a Contingent Value Right (CVR) of $6.00 per share upon U.S. regulatory approval of efruxifermin (EFX) for treating MASH-related cirrhosis by 2031. The deal includes a 19% premium to Akero’s 30-day VWAP and a 42% premium to its May 19, 2025 closing price. Akero's EFX program aims to address MASH, and the ...
2025-10-09 10:01
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
Akero Therapeutics announced upcoming oral and poster presentations at the 76th AASLD Liver Meeting 2025 in Washington, DC. The presentations will highlight results from the 96-week Phase 2b SYMMETRY study assessing efruxifermin (EFX) in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH). Key findings include improvements in non-invasive fibrosis regression markers and portal hypertension, as well a...
2025-10-07 11:00
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
Results from Akero Therapeutics' Phase 2b HARMONY trial, published in *The Lancet*, demonstrate that efruxifermin (EFX) significantly reduced liver fibrosis and resolved steatohepatitis in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH). At 96 weeks, 49% of participants on 50mg EFX achieved fibrosis improvement without worsening of MASH, compared to 19% on placebo. Additionally, EFX improved liver injury marker...
2025-08-14 22:30
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
Akero Therapeutics announced that its management will present at the Jefferies Global Healthcare Conference on June 4, 2025. The presentation will be webcast live and archived on the company's website. Akero develops treatments for serious metabolic diseases like metabolic dysfunction-associated steatohepatitis (MASH). Its lead candidate, efruxifermin (EFX), is in Phase 3 trials. The company is based in South San Francisco.
2025-05-28 11:00
Aker ASA’s Earnings Call: Growth Amid Challenges
Aker ASA (($NO:AKER)) has held its Q4 earnings call. Read on for the main highl...
2025-02-17 08:25
Aker ASA to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 17, 2021 / Aker ASA (NASDAQ:AKER) will be ...
2021-02-17 19:45
Akers Biosciences Responds to Erroneous Earnings Call Press Release
Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER) confirmed that a press r...
2021-02-17 18:45
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Akers Biosciences, Inc. (NASDAQ:AKER)
BALA CYNWYD, PA / ACCESSWIRE / November 12, 2020 /Law Office of Brodsky & S...
2020-11-13 07:57
